Research programme: peptide therapeutics - PhaseBio Pharmaceuticals

Drug Profile

Research programme: peptide therapeutics - PhaseBio Pharmaceuticals

Alternative Names: Insulin-ELP; PB 1120; VIP-ELP-120

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Biopolymers; Drug conjugates; Insulins; Pancreatic hormones; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants; Vasoactive intestinal peptide receptor agonists; Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis
  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC)
  • 01 May 2016 Preclinical trials in Cystic fibrosis in USA (unspecified route)
  • 01 Jan 2012 Preclinical trials in Diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top